Wells Fargo lowered the firm’s price target on Q32 Bio (QTTB) to $15 from $16 and keeps an Equal Weight rating on the shares. While bempi’s ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned an average recommendation of “Hold” from the eight research ...

No. 7 train service is facing delays Thursday afternoon after a person was struck by a train in Corona, according to MTA ...

Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today ...

W ALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss of $1.16 ...

Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it pivots focus over to its alopecia areata treatment, bempikibart, amid a corporate restructure and job cuts.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss ...

March 11, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis ...